Non-Invasive MRD Detection: The Third Solution for the Myeloma Monitoring Dilemma

Marker X CO., LTD. has announced its participation in the Healthcare+ Expo, Taiwan 2025, where it will showcase MyeloTrak, a groundbreaking mass spectrometry-based solution designed to transform the management of Multiple Myeloma (MM).

Multiple Myeloma (MM) patients face a significant challenge: finding a safe, painless, and highly effective monitoring regimen for recurrence. Advances in medicine have extended patient survival to 8~10 years, but this longevity is often accompanied by the risk of multiple relapses. Each recurrence complicates treatment and increases financial burden. Globally, the focus of MM care has shifted toward the precise monitoring of Measurable Residual Disease (MRD).

However, clinical hematologists face a monitoring dilemma:

1. Low Sensitivity: Traditional methods like Serum Protein Electrophoresis (SPEP) lack the sensitivity needed for effective early MRD detection.

2. High Burden: Bone marrow aspiration is highly invasive and costly, making it unsuitable for frequent, long-term follow-up.

These limitations restrict the frequency of monitoring, hindering the timely adjustment of treatment strategies.

Marker X’s newly launched MyeloTrak , a novel MRD detection method utilizing mass spectrometry, successfully offers a third, revolutionary solution between the low-sensitivity traditional methods and the invasive bone marrow biopsy. MyeloTrak requires only 5ml of peripheral blood, yet achieves over one thousand fold greater sensitivity than traditional electrophoresis. This non-invasive approach significantly boosts patient compliance for long-term monitoring, fundamentally solving the issue of interrupted surveillance. Crucially, it represents a key enabler of proactive clinical management, embodying the core philosophy that “Monitoring is Treatment.”

Mass Spectrometry Analysis of Personalized M-Protein Sequence for Precision Decision-Making

The core technology of MyeloTrak involves dissociating proteins followed by mass spectrometry analysis of personalized peptide sequences, specifically targeting Clonotypic Peptides for MRD detection. This method establishes an individualized M-protein fingerprint for each patient. This innovative liquid biopsy approach provides critical advantages for MM clinical decision-making:

• Ultra-Early Relapse Warning: MyeloTrak’s high sensitivity allows MM monitoring to capture the MRD signal at the minimal residual disease level. Clinical case data indicate the potential for detecting recurrence trends 4 ~ 7 months earlier. This crucial window of opportunity can transform “passively awaiting relapse” into “proactively intervening in treatment,” giving hematologists the necessary buffer to adjust maintenance therapy or increase monitoring frequency.

• Interference Exclusion: MyeloTrak’s proprietary analysis method effectively excludes potential interference from therapeutic monoclonal antibodies (such as Daratumumab), ensuring the stability and reliability of MM monitoring data. This guarantees that treatment strategies can be synchronized with the patient’s biomarker status in a timely and accurate manner, maximizing efficacy and reducing subsequent healthcare costs.

Through MyeloTrak’s non-invasive and high-frequency MRD monitoring method, physicians gain precise control over the dynamic progression of Multiple Myeloma. This elevates MRD monitoring from a mere “assessment tool” to a “treatment optimization instrument,” realizing a more personalized MM management model.

Accelerating Clinical Adoption Through Research Collaboration

MyeloTrak’s MRD monitoring method has already gained recognition from top-tier clinical institutions. We are currently collaborating on a clinical research project with a renowned medical center to actively validate MyeloTrak’s clinical value in the Multiple Myeloma setting. Furthermore, the results of this research are scheduled for publication in a leading international journal. This signifies a significant stride from laboratory innovation towards real-world clinical application, positioning Taiwanese biotechnology to join the global MRD monitoring trend.

With the technology protected by a pending US provisional patent, Marker X invites experts, potential investment partners, and hospital representatives to accelerate the adoption of this critical MM monitoring method. We are actively seeking diverse strategic cooperation opportunities:

• Clinical Research Partners: We invite more hematology-oncology physicians to join MRD monitoring clinical studies to accelerate the validation of MyeloTrak™ across different MM subtypes.

• Upstream and Downstream Partners: We seek collaboration in In Vitro Diagnostics (IVD) regulatory strategy, channel expansion, or technology licensing to accelerate the product’s global market penetration.

• Healthcare Payers and Procurement Decision-Makers: We aim to integrate MyeloTrak’s MRD monitoring method into commercial insurance coverage. By offering a high-value, cost-effective solution, we hope to extend the benefits of precision monitoring to a greater number of Multiple Myeloma patients.

We sincerely invite all parties to visit our booth at this year’s Taiwan Healthcare+ Expo to witness this innovative technology and join us in bringing the philosophy that “Monitoring is Treatment” to the care of every Multiple Myeloma patient.

About Marker X CO., LTD.

Marker X CO., LTD. is a leading Taiwan biotech company specializing in novel biomarker development and proteomics analysis. Driven by a commitment to lead in proteomic diagnostics, the company leverages cutting-edge technology to translate innovative disease-related biomarkers into clinically actionable diagnostic applications, contributing substantially to global health.

Press Contact：

Debby Chen

support@marker-x.com